Onco Actu du 8 juin 2020

	2.5 ETIOLOGIE - GÉNOME
Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type [Genome Web] A team led by investigators at St. Jude Children's Research Hospital did whole-genome sequencing on blood samples from 4,402 pediatric cancer survivors in the St. Jude Lifetime Cohort, including 495 individuals who went on to develop more than 1,200 secondary neoplasms, focusing on pathogenic germline alterations affecting more than 100 genes from half a dozen DNA repair pathways.
	5. TRAITEMENTS
Experts release new guidelines for studies into most effective treatments for HPV-positive throat cancer [University of Birmingham] Heightened caution is needed when considering de-escalation trials for patients with Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC), to ensure minimal harm to patients, new guidelines from a group of international head and neck cancer experts have suggested.
	5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug [Xconomy] The Legend drug targets a cancer protein called B-cell maturation antigen (BCMA). It’s found in abundance on the surface of multiple myeloma cells. There are no FDA-approved BCMA-targeting drugs yet, but the JNJ-4528 data make it a strong contender to become the first.
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020 [Biopharma Dive] Legend Biotech, a subsidiary of Hong Kong firm GenScript, has become increasingly known in U.S. biotech circles since cutting a deal with Johnson & Johnson two and a half years ago.
Legend fetches $424 million, emerges as biggest winner yet in pandemic IPO boom as shares soar [EndPoints] Legend Biotech, the Nanjing-based CAR-T developer, has raised $424 million on the Nasdaq. The biotech had originally filed for a still-hefty $350 million. It didn’t stop there. Its shares rocketed up more than 60% on its first day of trading.
	5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
Immunotherapy treatment recommended for advanced small cell lung cancer [Cancer Research UK] In trial involving 403 patients, patients taking atezolizumab lived for an average of 12.3 months, compared with 10.3 months in group taking a placebo and chemotherapy. But the long-term benefits of the combination are unclear, as clinical trial data did not suggest a significant survival benefit from adding atezolizumab beyond 30 months.
	5.2.2 PHARMA - FUSIONS & ACQUISITIONS
Does AstraZeneca CEO Pascal Soriot really want to merge with Gilead? A Bloomberg story suggests he’s interested -- but it's hard to see why [EndPoints] At this stage, there could only be 2 people who have the biggest share of the say here. One is AstraZeneca CEO Soriot and the other is Gilead CEO Dan O’Day. And they know each other well, having once held overlapping positions at Roche.
	5.4.2 TRAITEMENTS - ECONOMIE - IQWIG
Ribociclib in breast cancer: added benefit for certain women after menopause [IQWIG] According to the findings, an added benefit is not proven for initial endocrine therapy with ribociclib in combination with the aromatase inhibitor letrozole and for subsequent endocrine therapy with ribociclib plus fulvestrant. For initial endocrine therapy with ribociclib plus fulvestrant, in contrast, there is now an indication of a minor added benefit.
	5.5 ASCO
Clifford Hudis: What a virtual meeting can accomplish—and what a virtual meeting cannot accomplish [The Cancer Letter] “Maybe this is ultimately why, like in the prior pandemics that have racked the world over the eons, humans still come back to the same behaviors they enjoy. And this is why I would expect that we will get back to face-to-face meetings when it is safe.”
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Scientists’ worlds will shrink in the wake of the pandemic [Nature] Researchers expect long-term changes that reduce travel for work and conferences: part 6 in a series on science after the pandemic.
ASCO data will provide actionable insights from the COVID-19 pandemic—for every patient [The Cancer Letter] We also set out to collect data and, currently, have three lines of sight into the COVID-19 impact.